Biosimilar Growth to Be Led by Insulin and Monoclonal Antibodies: A Market Overview

The global biosimilar market is expected to grow at a compound annual growth rate (CAGR) of 18.32% from 2024 to 2034. By the end of the forecast period, the market is projected to reach USD 125.32 billion, up from an estimated value of USD 27.46 billion in 2024. This robust growth is driven by the increasing demand for affordable alternatives to expensive biologic treatments, advancements in biotechnology, and the expansion of healthcare access worldwide. 

Market Scope 

Market Size in 2024: USD 27.46 Billion 

Market Forecast in 2034: USD 125.32 Billion 

CAGR (2024-2034): 18.32% 

Base Year: 2023 

Historic Data: 2016-2022 

Forecast Period: 2024-2034 

Report USP: Includes analysis of production, consumption, company share, company heatmap, production capacity, growth factors, and more. 

Request Sample Copy: https://wemarketresearch.com/reports/request-free-sample-pdf/biosimilar-market/5  

Key Market Players 

Pfizer Inc. 

Novartis AG 

Orion Pharma AB 

Biocon 

Coherus BioSciences, Inc. 

Amgen Inc. 

Samsung Bioepis 

Takeda Pharmaceutical Company Limited 

Bristol-Myers Squibb Company 

Merck KGaA 

Eli Lilly and Company 

Teva Pharmaceutical Industries Ltd. 

Bayer AG 

Market Drivers and Opportunities 

The key drivers of the biosimilar market include: 

Cost-Effectiveness: Biosimilars offer a more affordable alternative to expensive branded biologics, making them attractive to both healthcare providers and patients. 

Regulatory Support: Many countries are establishing regulations that promote the approval and use of biosimilars, providing a strong foundation for market growth. 

Increasing Chronic Diseases: The rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the demand for biologics, and subsequently biosimilars. 

Aging Population: The growing elderly population worldwide is a significant driver of biosimilar demand, as older individuals typically suffer from more chronic conditions requiring ongoing treatment. 

Challenges 

While the biosimilar market is growing, it faces challenges such as: 

Regulatory Hurdles: Navigating the approval process for biosimilars in different countries can be complex and time-consuming. 

Market Competition: As more companies enter the biosimilar space, competition is intensifying, which may impact pricing and market share. 

Physician and Patient Adoption: Some healthcare providers and patients remain hesitant to switch from branded biologics to biosimilars due to concerns about efficacy and safety. 

Access Report: https://wemarketresearch.com/reports/biosimilar-market/5